Parkinson's disease

Lancet. 1990 Apr 21;335(8695):948-52. doi: 10.1016/0140-6736(90)91006-v.
No abstract available

Publication types

  • Review

MeSH terms

  • 1-Methyl-4-phenylpyridinium / adverse effects
  • Adrenal Glands / transplantation
  • Adult
  • Antiparkinson Agents / adverse effects
  • Antiparkinson Agents / therapeutic use
  • Brain Chemistry
  • Child
  • Child, Preschool
  • Cytoplasmic Granules / pathology
  • Dyskinesia, Drug-Induced / etiology
  • Environmental Pollutants / adverse effects
  • Fetus
  • Humans
  • Levodopa / adverse effects
  • Levodopa / therapeutic use
  • Middle Aged
  • Palliative Care
  • Parkinson Disease* / diagnosis
  • Parkinson Disease* / drug therapy
  • Parkinson Disease* / epidemiology
  • Parkinson Disease* / etiology
  • Prevalence
  • Research
  • Selegiline / therapeutic use
  • Substantia Nigra / drug effects
  • Substantia Nigra / pathology
  • Substantia Nigra / transplantation
  • Time Factors

Substances

  • Antiparkinson Agents
  • Environmental Pollutants
  • Selegiline
  • Levodopa
  • 1-Methyl-4-phenylpyridinium